C225 WITH CHEMORADIATION FOR POST-OP HEAD AND NECK SQUAMOUS CELL CANCER

该子项目是利用NIH/NCRR资助的中心赠款提供的资源的许多研究子项目之一。子项目和研究者（PI）可能从另一个NIH来源获得主要资金，因此可以在其他CRISP条目中表示。所列机构为中心，不一定是研究者所在机构。采用随机分配II期设计，评价两种使用EGFR抑制剂C225联合放化疗治疗高危头颈部术后患者的治疗方案。本试验旨在确定两种方案中的任何一种方案是否有足够的希望在随后的III期研究中进行。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. To evaluate, using a random assignment phase II design, two treatment regimens that utilize the EGFR inhibitor C225 in combination with chemoradiation in high-risk postoperative head and neck patients. This trial is designated to determine if either regimen is promising enough to be pursued in a subsequent phase III study.